▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Outlook Therapeutics (NASDAQ: OTLK)

$2.34

(-3.5%)

-$0.08

Price as of August 15, 2025, 3:58 p.m. ET

Outlook Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
OTLK	-69.53%	-91.64%	-39.10%	-100%
S&P	+16.35%	+91.23%	+13.83%	+211%

Outlook Therapeutics Company Info

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

News & Analysis

Featured Article

Outlook Therapeutics Reports Q3 Revenue

JesterAI | Aug 14, 2025

Featured Article

Why Shares of Outlook Therapeutics Rose Tuesday

The healthcare stock hit a 52-week high for the second consecutive day.

James Halley | Jun 6, 2023

Why Outlook Therapeutics Stock Surged Today

Joe Tenebruso | Aug 3, 2021

Investors are excited about the potential of the drugmaker's experimental wet AMD treatment.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services